Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.55 |
| ▸ | SCN2B | O60939 | 16/20 | 0.55 |
| ▸ | SCN1B | Q07699 | 16/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN1A | P35498 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464430 | 0.87 | SCN9A (0.58) | SCN9ASCN2BSCN1BSCN5ASCN8A | |
| SCHEMBL15465777 | 0.86 | SCN9A (0.58) | SCN9ASCN2BSCN1BSCN5ASCN8A | |
| SCHEMBL15465636 | 0.82 | SCN9A (0.56) | SCN9ASCN2BSCN1BSCN5ASCN8A | |
| SCHEMBL15465951 | 0.81 | SCN9A (0.57) | SCN9ASCN2BSCN1BSCN5ASCN8A | |
| SCHEMBL15464956 | 0.79 | SCN9A (0.67) | SCN9ASCN2BSCN1BSCN5ASCN8A | |
| SCHEMBL17270553 | 0.77 | SCN9A (0.49) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL17270538 | 0.76 | SCN9A (0.47) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL327000 | 0.75 | PTPN22 (0.35) | — | |
| SCHEMBL15465775 | 0.74 | SCN9A (0.46) | SCN9ASCN2BSCN1BSCN5ASCN8A | |
| SCHEMBL15465365 | 0.73 | SCN9A (0.84) | SCN9ASCN2BSCN1BSCN5ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| US-8889741-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | SCN9A 64/4885SCN2B 21/4885SCN1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.